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Microcin C is a ribosome-synthesized heptapeptide that contains
a modified adenosine monophosphate covalently attached to the
C-terminal aspartate. Microcin C is a potent inhibitor of bacterial cell
growth. Based on the in vivo kinetics of inhibition of macromolecular
synthesis, Microcin C targets translation, through a mechanism that
remained undefined. Here, we show that Microcin C is a subject of
specific degradation inside the sensitive cell. The product of degrada-
tion, amodifiedaspartyl-adenylatecontaininganN-acylphosphorami-
date linkage, strongly inhibits translation by blocking the function of
aspartyl-tRNA synthetase.
Microcins are a class of small (10 kDa) ribosomally synthesized
peptide antibiotics produced by Enterobacteriaceae (1). Whereas some
microcins are active as unmodified peptides (2), others are produced as
polypeptide precursors that are heavily modified by dedicated matura-
tion enzymes (3). Interest is attached to such post-translationally mod-
ified microcins due to their highly unusual structures and the fact that
they target important cellular processes that are attractive targets for
antibacterial drug development.
Genes responsible for microcin production are usually plasmid-
borne. Plasmids encoding microcin structural and maturation genes
also encode determinants of immunity specific to the microcin pro-
duced. Based on cross-immunity, post-translationally modified mic-
rocins can be subdivided into the B, C, and J types. Microcin B
(MccB)4 is a 43-residue peptide with 8 thiazole and oxazole rings that
are synthesized by the McbBCD maturation enzyme complex from
multiple serine and cysteine residues present in the MccB precursor
(4). MccB is a potent inhibitor of DNA gyrase; it traps the enzyme at
the stage of DNA strand passage (5). Microcin J, a 21-amino acid
peptide, contains an unusual lactam bond between its N-terminal
glycine and the -carboxyl group of an internal glutamate; it assumes
a highly unusual threaded-lasso structure (6–8). MccJ inhibits bac-
terial RNA polymerase by occluding a narrow channel that is used to
traffic transcription substrates, NTPs, to the catalytic center of the
enzyme (9, 10).
The structure of the subject of this study,Microcin C (McC) is shown
in Fig. 1A. McC is a heptapeptide containing a modified adenosine
monophosphate covalently attached to its C terminus through an
N-acylphosphoramidate linkage (11, 12). The phosphoramidate group
of the nucleotide part ofMcC is additionally modified by a propylamine
group. Additionally, in mature McC, the peptide moiety, which is
encoded by the mccA gene, is modified and the C-terminal aspara-
gine residue specified by mccA is converted to an aspartate (18, 19),
through an unknown mechanism. In vivo, McC appears to target
translation (12). Guijarro et al. (12) also reported that large concen-
trations of McC, as well as of synthetic peptide of the same sequence
but without the nucleotide modification, mildly inhibit translation
in vitro. They therefore concluded that the peptide part of McC is
responsible for translation inhibition, whereas the nucleotide part is
involved in McC transport into the cell. Here, we define the molec-
ular mechanism of McC action. Contrary to the suggestion of Gui-
jarro et al. (12), we find that the peptide moiety of McC allows cell
entry, whereas the nucleotide part is critical for translation inhibi-
tion. We show that inside the cell, McC is specifically degraded and
that the product of degradation, a modified aspartyl-adenylate,
strongly inhibits translation by preventing the synthesis of amino-
acylated tRNAAsp by aspartyl-tRNA synthetase.
EXPERIMENTAL PROCEDURES
Preparation of McC—The Escherichia coli strain TG1 harboring
McC-producing plasmid pBM43 was grown for 18 h at 37 °C in M63
minimummedium (13) containing 0.2% glucose and 1 mg/liter of thia-
mine. Cells were removed by centrifugation and the cultured medium
was loaded onto Sep-Pak C8 cartridge (Waters). The cartridge was
washed with water followed by a 0.1% aqueous trifluoroacetic acid
wash, and bound material was eluted stepwise with 5, 10, and 20%
acetonitrile in 0.1% trifluoroacetic acid. The 10% acetonitrile frac-
tion was concentrated by lyophilization, dissolved in water, and sub-
jected to reverse phase-HPLC (1 ml/min) on a ReproSil-Pur 300
ODS-3 column (5 m, 250  4 mm) using a 0–20% linear gradient of
acetonitrile in 0.1% trifluoroacetic acid. The total gradient volume
was 50 ml. Pure McC eluted as a single peak; it was lyophilized,
dissolved in water, and stored at 20 °C. The yield of chromato-
graphically and mass spectrometrically pure McC ranged from 5 to
10 mg/liter of cultured medium.
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Preparation of Cell Extract forMcCProcessing—McC-sensitiveE. coli
B cells were grown at 37 °C to A600 0.5 in 1 liter of M63 medium sup-
plemented with 0.2% glucose and 0.1% yeast extract. Cells were col-
lected by centrifugation, washed with 20 mM Tris-HCl, pH 7.5, resus-
pended in 3 ml of the same buffer, and disrupted by sonication on the
Branson Ultrasonics sonifier with a microtip (5  10 s pulses, at maxi-
mal power setting). The lysate was centrifuged at 30,000  g for 30min.
The supernatant (total protein concentration of 20 mg/ml) was divided
into aliquots and stored at 70 °C until further use.
McC Processing—250 g of McC was dissolved in 150 l of 25 mM
Tris-HCl, pH 8.0, 2 mM MgCl2 and combined with 50 l of cell extract
prepared as described above. The reactionwas incubated for 1 h at 37 °C
with continuous shaking. The reaction was terminated by the addition
of an equal volume of 100% acetonitrile, 0.1% trifluoroacetic acid. After
a 30-min incubation at 4 °C, proteins were removed by centrifugation
and the pellet was extracted three times with 200 l of water. The
extracts were pooled, lyophilized, redissolved in water, and fractionated
on a ReproSil-Pur 300ODS-3 column (5m, 250 4mm). The column
was first developed (0.5 ml/min) isocratically with 10mM (NH4)2HPO4,
pH 7.6, followed by a linear (0–60%) gradient of acetonitrile in the same
buffer. UV-absorbing fractions were collected, lyophilized, dissolved in
water, and tested in an in vitro translation system and by mass spec-
trometry. Active, processedMcC eluted at 11.4min during the isocratic
part of chromatography. Intact McC eluted at 27.2 min by 50% aceto-
nitrile. Processed McC prepared in this way was chromatographically
and mass spectrometrically pure. The material was lyophilized and dis-
solved in water. The concentration was determined using UV absorp-
tion at 260 nm (calculated extinction coefficient of processed McC
16,500 g/mol).
Coupled in Vitro Transcription/Translation—Transcription and trans-
lation (coupled system) in E. coli S30 extract (Ref. 14, final total protein
concentration, 2.5 mg/ml) was carried out at 30 °C in the presence of 100
mM Hepes KOH, pH 8.0, 2% PEG8000, 0.1 mM EDTA, 2 mM DTT, 0.5
g/liter of bulkE. coli tRNA,0.1 g/liter of folinic acid, 0.1mMluciferin, 20mM
acetyl phosphate, 20 mM phosphoenolpyruvate, 1 mM GTP, 1 mM UTP, 1
mMCTP, 1.4mMATP, 11.5mMMg(OAc)2, 237mMKOAc, 0.5mMof each
amino acid, 15MpT7luc plasmid (15), 0.04 g/liter of pyruvate kinase, and
2units/l ofT7RNApolymerase.The reactionmixturewasplaced into the
cell of a Hidex Triathler luminometer and the appearance of luciferase
activity in the course of translation was monitored.
In Vitro Translation—Luciferase mRNA was prepared by in vitro
transcription of the pT7luc plasmid with T7 RNA polymerase (22) and
purified by phenol-chloroform treatment and precipitation with 3 M
LiCl. Translation in E. coli S30 extract (Ref. 14, final total protein con-
centration, 3mg/ml) was carried out at 30 °C in the presence of 26.1mM
Hepes KOH, pH 7.6, 4% PEG8000, 1.7 mM DTT, 0.175 g/liter of bulk
E. coli tRNA, 0.03 g/liter of folinic acid, 0.1mM luciferin, 80mM creatine
phosphate, 0.8 mM GTP, 1.2 mM ATP, 10 mM Mg(OAc)2, 125 mM
KOAc, 0.34mM each amino acid, 74 nM luciferasemRNA, 0.25 g/liter of
creatine kinase. The reaction progression was monitored as above.
Translation in wheat germ S30 extract (Ref. 16, final total protein
concentration 3 mg/ml) was carried out at 30 °C in the presence of
26.1 mM Hepes KOH, pH 7.6, 2% glycerol, 1.6 mM DTT, 0.05 g/liter
of bulk yeast tRNA, 0.1 mM luciferin, 16 mM creatine phosphate, 0.4
mM GTP, UTP, CTP, 1 mM ATP, 3 mM Mg(OAc)2, 70 mM KOAc, 0.2
mM each amino acid, 0.45 mM spermidine, 74 nM luciferase mRNA,
and 0.1 g/liter of creatine kinase. The reaction progression was mon-
itored as above.
In Vitro Translation of Poly(U) RNA—Poly(U) RNA translation in 3
mg/ml E. coli S30 extract (14) was carried out at 30 °C in the presence of
26.1mMHepes KOH, pH7.6, 4% PEG8000, 1.7mMDTT, 0.175 g/liter of
bulk E. coli tRNA, 0.03 g/liter of folinic acid, 0.1 mM luciferin, 80 mM
creatine phosphate, 0.8 mM GTP, 1.2 mM ATP, 10 mM Mg(OAc)2, 125
mM KOAc, 74 nM poly(U) RNA (molecular mass 800–1000 kDa,
Sigma), 0.25 g/liter of creatine kinase. The reaction mixture contained
[14C]Phe. The compound, which limits the reaction, was the poly(U)
RNA.
Preparation of S100 Cell Extract from E. coli—E. coli MRE600 cells
were grown to A600 0.8 in LB medium. Cells were collected by centrif-
ugation, and washed with 40 mM Tris-HCl, pH 7.6, 10 mM Mg(OAc)2,
50 mM KOAc, 0.1 mM EDTA, 1 mM DTT. The cell pellet was resus-
pended in an equal volume of the same buffer and disrupted by a French
press (pressure 1000 bar). The lysate was next centrifuged at 30,000  g
for 30 min. The supernatant was centrifuged at 100,000  g for 2.5 h.
The supernatant was loaded on the columnwith DE-52 cellulose, equil-
ibrated by 40mMTris-HCl, pH 7.6, 10mMMg(OAc)2, 50mMKOAc, 0.1
mM EDTA, 1 mM DTT. The column was washed by the same buffer.
The enzyme fraction was eluted by 40 mM Tris-HCl, pH 7.6, 10 mM
Mg(OAc)2, 250 mM KOAc, 0.1 mM EDTA, 1 mM DTT (total protein
concentration was 10 mg/ml).
Francisella tularensis AspRS—TheAspRSgene (aspS)was amplifiedby
PCR,with an encodedC-terminalHis6 epitope, using genomicF. tularensis
strain LVS DNA as template, the primers used were 5-CATATGAGAA-
CACATTATAGTTCA-3and5-GGATCCTAATGGTGATGGTGAT-
GGTGCGCGCCCCTTTCTTCTTTCTTAACA-3 and Pfu DNA
polymerase (Stratagene). The PCR product was cloned into PCR-Blunt
II-TOPOvector (Invitrogen), the sequenceof the constructwas confirmed,
and the corresponding NdeI-BamHI-digested fragment ligated into NdeI-
BamHI-digested pET11a.
Production of His6-tagged AspRS was done by transforming
BL21(DE3) with pET11a-FTAspRS and growing the resulting strain
using the Overnight ExpressTM Autoinduction System 1 (Novagen)
according to the manufacturer’s instructions. Cell-free extract was pre-
pared by re-suspending E. coli cells in lysis buffer (30mMTris, pH 8, 300
mMNaCl, 10mM imidazole, 10% glycerol) and passage through a French
pressure cell followed by centrifugation at 75,000 g , at 4 °C for 45min.
The resulting supernatant was applied to a column containing BD
TALONaffinity resin (BDBioscience), washed extensively with the lysis
buffer, and AspRS-His6 subsequently eluted using the lysis buffer sup-
plemented with 300 mM imidazole. Fractions containing AspRS-His6
(judged by Coomassie Brilliant Blue staining after SDS-PAGE to be
95% pure) were pooled, dialyzed extensively against storage buffer (50
mMTris, pH 7.5, 5 mM 2-mercaptoethanol, 100mMNaCl, 1 mM EDTA,
50% glycerol), and stored at 20 °C. The concentration of AspRS-His6
was determined by active site titration as previously described (17), and
the reactions were performed in duplicate for 5 and 10 min.
tRNA Aminoacylation Reaction—Aminoacylation reaction in E. coli
S100 extract (final total protein concentration 0.1 mg/ml) was carried
out at 30 °C in the presence of 30 mM Hepes KOH, pH 7.6, 1 mM DTT,
5 g/liter bulk of E. coli tRNA, 0.1 mM EDTA, 3 mM ATP, 8 mM
Mg(OAc)2, 30 mM KOAc, and 40 M of the specified amino acid. The
reaction products were either precipitated in cold 5% trichloroacetic
acid and subjected to scintillation counting or purified by phenol-chlo-
roform treatment/ethanol precipitation and added to in vitro transcrip-
tion-translation reactions. At the conditions used, the aminoacylation
reactions were limited by tRNA, because increase of this component
only resulted in a proportional increase in trichloroacetic acid-insoluble
radioactivity. Aminoacylation by purified F. tularensis AspRS was con-
ducted at identical conditions with 40 nM active F. tularensis AspRS
used instead of the S100 extract.
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The aminoacylation reaction in 1% wheat germ S30 extract was car-
ried out at 30 °C in the presence of 30 mM Hepes-KOH, pH 7.6, 1 mM
DTT, 5 g/liter of bulk yeast tRNA, 0.1 mM EDTA, 3 mM ATP, 8 mM
Mg(OAc)2, 30 mM KOAc, and 40 M of amino acid of choice. The
reaction products were precipitated in cold 5% trichloroacetic acid and
subjected to scintillation counting.
ATP-PPi Exchange Reaction—The reaction was carried out at 37 °C
in 100 mM Na-Hepes, pH 7.2, 30 mM KCl, 10 mM MgCl2, 2 mM NaF,
FIGURE 1. Processed McC inhibits translation in vitro. A, the structure of McC. B, in vitro transcription-translation of the luciferase gene in the presence of McC. The luciferase gene
was used as a template for in vitro transcription-translation in E. coli S30 extract as described under “Experimental Procedures” in the presence of 10 M intact McC or MRTGNAD
(peptide D) or MRTGNAN (peptide N) peptides. Water was added to the control reaction. A representative result from a series of three independent experiments is shown. C, in vitro
transcription-translation of the luciferase gene in the presence of processed McC. The results of the in vitro transcription-translation of the luciferase gene in the presence of 10 M
intact McC or the corresponding amount of McC that has been preincubated with E. coli extract (processed McC) are presented. Water (control) or E. coli extract preincubated without
McC (cytoplasm) was added to control reactions. D, in vitro translation of luciferase RNA in the presence of processed McC. The luciferase RNA was translated in vitro using E. coli S30
extract as described under “Experimental Procedures” in the presence of 10 M intact McC or the corresponding amount of processed McC.
FIGURE 2. Effect of McC on poly-Phe synthesis in
a poly(U)-directed in vitro translation system.
In vitro translation of the poly(U) template was
performed in the presence or absence of 10 M
intact McC or the corresponding amount of pro-
cessed McC.
Microcin C Targets Aspartyl-tRNA Synthetase
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2 mM ATP, 2 mM [32P]PPi (1 cpm/pmol), 2 mM Asp, and 30 nM F.
tularensis AspRS. After 1–10 min, 25 l of the reaction were
removed and added to 975 l of solution containing 1% charcoal
(NoritA), 5.6% perchloric acid, and 75mM PPi. The radiolabeled ATP
bound to the charcoal was filtered through a 3MM Whatman filter
disc under vacuum, washed 3 times with 5 ml of water and once with
5 ml of ethanol. The filters were dried and the radioactivity was
counted by liquid scintillation counting (Ultima Gold, Packard
Corp.).
RESULTS
McC Has No Effect on in Vitro Translation—It has previously been
reported that the addition of 10M intactMcC led to50% inhibition of a
coupled E. coli in vitro transcription-translation system over 30 min (12).
However, we failed to observe any effect of the addition of 10 M highly
pure, biologically active McC to the luciferase gene in vitro transcription-
translation systemafter asmuchas a60-min incubation (Fig. 1B). It has also
been reported that the peptideMRTGNAD, corresponding to the peptide
FIGURE 3. Processed McC inhibits aspartyl-
tRNA synthetase. A, the indicated amino acids
were used in in vitro tRNA aminoacylation reac-
tions in the presence of 10 M intact McC or the
corresponding amount of processed McC. For
each amino acid tested, aminoacylation observed
in the presence of intact McC was identical to ami-
noacylation when water was added to the reac-
tion instead of McC (data not shown). The bars
show the mean values obtained in three inde-
pendent experiments. B, the results of the lucifer-
ase gene transcription-translation in the presence
of processed McC with the addition of aminoacy-
lated tRNAAsp or tRNAPhe at 0 and 26-min time
points are presented. C, the results of tRNAAsp
aminoacylation by 40 nM F. tularensis AspRS in the
presence of increasing concentrations of pro-
cessed McC are shown. D, [32P]PPi-ATP exchange
by 30 nM F. tularensis AspRS in the presence of pro-
cessed and intact McC. Circles, no McC; triangles,
200 nM intact McC; squares, 100 nM processed
McC; diamonds, 300 nM processed McC.
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moiety of mature McC inhibits in vitro translation as efficiently as intact
McC (12).We synthesized theMRTGNADpeptide as well as theMRTG-
NAN peptide encoded by mccA, the structural gene for McC (18, 19),
and confirmed the previous result (12) that such peptides have no
effect on the growth of McC-sensitive cells (data not shown). The
addition of these McC peptides (10 M) had no significant effect on
the coupled in vitro transcription-translation system (Fig. 1B).
Incubation with Crude Cell Extract Inactivates Antibiotic Activity of
McC but Makes It a Potent Inhibitor of Translation in Vitro—We
hypothesized that the inability of pure McC to inhibit transcription-
translation in vitro is due to a lack of processing that is required to
convert it into active inhibitor. To test this hypothesis, McC was incu-
bated with cell extract prepared from McC-sensitive E. coli cells as
described under “Experimental Procedures.” The incubation resulted in
inactivation of McC as judged by a dramatic decrease in its ability to
produce growth inhibition zones on lawns of sensitive E. coli cells (data
not shown). However, McC that was incubated with the cell extract
(“processed McC”) strongly inhibited the coupled transcription-trans-
lation system (Fig. 1C), as well as the luciferase mRNA translation sys-
tem (Fig. 1D). The addition of cell extract alone had no effect.
Whereas the observation above is consistent with an idea thatMcC is
converted into an active form upon incubation with cell extract, a ques-
tion arises why this conversion does not happen in the in vitro transcrip-
tion-translation reaction that contains the S30 extract ofMcC-sensitive
MRE600 E. coli cells. The answer to this question appears to be that
efficient processing of intact McC requires a high concentration of cell
extract (or long incubation times) that exceed the cell extract concen-
tration or incubation times used for in vitro transcription-translation
experiments. In agreementwith this idea, incubation of intactMcCwith
the in vitro transcription-translation system for 70 min, the maximal
time of in vitro transcription-translation in our experiments did not
result in inactivation ofMcC as judged by its ability to inhibit the growth
of sensitive cells (data not shown, recall that processed McC has no
effect on cell growth, above). Thus, we conclude that intact McC is
either processed in the cell extract or coupled with a factor(s) that con-
verts it into an active, inhibitory form.
Active Form of McC Inhibits Aspartyl-tRNA Synthetase—What is the
mechanism of translation inhibition by processed McC? A clue to this
question is provided by the fact that no inhibition of poly(U)-primed
translation is observed with either intact or processed McC (Fig. 2).
Thus, it appears that the function of translation elongation factors and
the elongation properties of the ribosome are not affected by processed
McC. Therefore, the likely targets could be the process of translation
initiation or the function of tRNAs other than tRNAPhe. We tested the
latter possibility by determiningwhether processedMcC can inhibit the
tRNA aminoacylation reaction. The results are presented in Fig. 3A. As
can be seen, intactMcChad no effect on tRNAaminoacylation by any of
the 6 amino acids tested. In contrast, processed McC specifically inhib-
ited tRNA aminoacylation by aspartate and, to a much lesser extent, of
asparagine, but had no effect on tRNA aminoacylation by other amino
acids tested. The results presented above suggest that the inhibition of
aspartyl-tRNA synthetase (AspRS) may be responsible for the observed
inhibition of in vitro translation by processed McC.
To test this idea, we supplemented the in vitro luciferase gene tran-
scription-translation reaction inhibited by the addition of processed
McC with aminoacylated tRNAAsp; tRNAPhe was used as a control. The
results are presented in Fig. 3B. As can be seen, the addition of amino-
acylated tRNAAsp but not tRNAPhe stimulated luciferase production.
Thus, processedMcC inhibits translation in vitro because it specifically
inhibits the production of aminoacylated tRNAAsp.
The final level of luciferase activity achieved after the addition of
aminoacylated tRNAAsp wasmuch lower and the time during which the
increase in the activity occurred was much shorter than seen in the
absence of processedMcC, suggesting that the exogenously added ami-
noacylated tRNAAsp was quickly used up and no regeneration of amino-
acylated tRNAAsp occurred in the presence of processedMcC. Indeed, the
secondadditionofaminoacylated tRNAAsp led toa further increase in lumi-
nescence. The second addition of aminoacylated tRNAAsp led to a rapid
increase in luciferase production, whereas a 10-min lag was observed
between the first addition of aminoacylated tRNAAsp and the appear-
ance of luciferase activity (a similar lag is observed in the absence of
McC, Fig. 1, B and C). This behavior is expected, because for luciferase
activity to appear, transcription of the luciferase genemust occur, trans-
lation of luciferase mRNA must be initiated, and the synthesis of the
entire luciferase polypeptide must be completed. These processes take
time and thus contribute to the observed lag in the appearance of lucif-
erase activity. When the first pool of exogenously added aminoacylated
tRNAAsp is exhausted, translation elongation is stopped and ribosomes
become stalled at Asp codons at various points of the luciferase mRNA.
The second addition of aminoacylated tRNAAsp to these “primed” ribo-
somes releases the translation block and leads to rapid increase in lucif-
erase production.
FIGURE 3—continued
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To demonstrate that processed McC directly inhibits the function of
AspRS in a pure system, we used a recombinant AspRS from F. tularen-
sis that shares 58% amino acid identity to its E. coli homolog. We rea-
soned that because bacterial AspRSs are highly conserved, and intact
McC is effective against a wide range of Gram-positive and Gram-neg-
ative bacteria (11), processed McC would be likely to inhibit the
F. tularensis enzyme. This expectationwas fulfilled. As can be seen from
Fig. 3C, when processedMcC was present in the reaction at concentra-
tions below 20 nM, it had little effect on tRNAAsp aminoacylation by
F. tularensis AspRS. Higher concentrations of processed McC effec-
tively inhibited tRNAAsp aminoacylation and no activity was detected
above 100 nM processed McC. Because the concentration of active
F. tularensis AspRS in the reaction was estimated at 40 nM, the result
suggests that a stable stoichiometric complex between the inhibitor and
the enzyme is readily formed.
To determine the effect of processedMcC on aspartyl-adenylate syn-
thesis, Asp-dependent [32P]PPi-ATP exchange reaction catalyzed by
F. tularensis AspRS was monitored in the presence of processed or
intact McC. The results, presented in Fig. 3D, clearly indicate that pro-
cessed McC inhibits the pyrophosphate exchange, whereas intact McC
FIGURE 4. E. coli cells overproducing D. radio-
durans AspRS become resistant to McC. The
growth of E. coli cells harboring a pET vector plas-
mid (A), or plasmids expressing D, radiodurans
ProRS (B), or AspRS (C) in the presence or absence
of 1 g/ml (0.85 M) McC is shown. The growth
curves shown are representative of a series of
independent experiments that were repeated
three times.
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has no effect on the reaction. Thus, the inhibition ofAspRS by processed
McC occurs at the first step of the aminoacylation reaction, namely
amino acid activation (Fig. 3D).
AspRS Is the in Vivo Target of McC—The results presented so far
demonstrate that processed McC inhibits translation in vitro by tar-
geting AspRS. We hypothesized that translation inhibition by McC
in vivo occurs for the same reason and that therefore AspRS is the
physiological target of McC. If this were the case, cells overexpress-
ing AspRS might become partially or completely resistant to McC.
To test this prediction, E. coli BL21(DE3) cells were transformed
with a pET vector-based plasmid overexpressing AspRS from D.
radiodurans (20). As a control, we used cells overexpressing plas-
mid-borne D. radiodurans ProRS (21) or cells carrying the pET vec-
tor alone. The levels of McC resistance were determined by adding 1
FIGURE 5. Identification of processed McC. A, the structure of the aspartyl adenylate analogue formed upon hydrolysis of the McC ultimate peptide bond. Molecular mass of the
compound shown is 519 Da. B, HPLC separation of intact McC (top panel ), cell extract (middle panel), and processed McC obtained by incubation of intact McC and cell extract (bottom
panel ). C, MALDI-TOF MS analysis of the indicated HPLC fraction that inhibited in vitro translation and aminoacylation of tRNAAsp was performed on a Bruker Ultraflex mass
spectrometer (reflector mode) using 2,5-dihydroxybenzoic acid as a matrix.
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g/ml (0.85 M) of McC to cell cultures growing in liquid LB
medium under conditions that induced expression of plasmid-borne
genes. Cell growth was next monitored over time. Cultures that did
not receive McC served as controls. The results are presented in Fig.
4. As can be seen, cells harboring the pET vector or overproducing
ProRS ceased growth upon the addition of McC. In contrast, the
McC had little effect on the growth of cells overproducing AspRS. The
results are therefore consistent with the hypothesis that AspRS is the in
vivo target of McC. It should be noted that the protection afforded by
overexpression of Deinococcus radiodurans AspRS was partial, and cell
growth was visibly inhibited in the presence of higher concentrations of
McC (data not shown). The results suggest that D. radiodurans AspRS
is also inhibited by McC, although the possibility that high concentra-
tions of McC disrupt cell growth by affecting other targets cannot for-
mally be excluded.
McC Processing Results in Hydrolysis of the Ultimate Peptide Bond—
The C-terminal residue of intact McC is an aspartate covalently
attached tomodified AMPmaking it similar to the natural intermediate
of the activation reaction catalyzed by AspRS, aspartyl adenylate. The
mode of action of processed McC made us hypothesize that the proc-
essing event involves cleavage of the last McC peptide bond with the
resultant generation of an aspartyl adenylate analogue (Fig. 5A) that
poisons AspRS. To test this hypothesis, intact McC was incubated with
cell extract and the reaction products were separated by reverse-phase
HPLC as described under “Experimental Procedures.” Under the chro-
matographic conditions used, intact McC elutes at 50% acetonitrile
(Fig. 5B, top panel). Upon incubation with the cell extract, the peak of
intact McC disappeared; instead, a peak that eluted during the isocratic
stage of the chromatography appeared (Fig. 5B, bottom panel). No such
peak was present in the cell extract (Fig. 5B,middle panel). Spectropho-
tometric analysis indicated that the new peak contained a nucleotide,
based on characteristic absorbance at 260 nm (data not shown). The
material from this peak inhibited the cell-free transcription-translation
system and the aminoacylation of tRNAAsp, whereas other HPLC frac-
tions did not (data not shown). When the active HPLC fraction was
analyzed byMALDI-MS, a mass ion of 518.9 Da was detected (Fig. 5C).
No such mass ion was detected in inactive fractions. In contrast, the
minor peaks seen in the mass spectrogram presented in Fig. 5C were
also seen in inactive fractions and must have come either from the
chromatographic buffer or mass spectrometry matrix. The calculated
mass of the hypothetical McC degradation product (Fig. 5A) is also 519.
Thus, the results of MS analysis are consistent with an idea that pro-
cessed McC is generated by hydrolysis of the ultimate peptide bond of
McC, which results in generation of an aspartyl adenylate analogue that
inhibits AspRS.
Processed McC Inhibits Aminoacylation by Eukaryotic AspRS—The
inhibitory product of McC processing is very similar to the natural
intermediate of the reaction catalyzed by AspRS and therefore likely
inhibits the enzyme by binding in the active site. Aminoacyl-tRNA
synthetases, including AspRS, are evolutionarily conserved enzymes
and eukaryal proteins can often functionally complement bacterial
enzymes in vitro and in vivo (see, for example, Moulinier et al., Ref.
22). Therefore, one can expect that processed McC may also inhibit
eukaryal AspRS. To test this prediction, we determined the effect of
processed McC on in vitro translation in a wheat germ extract. In
agreement with our hypothesis, processedMcC inhibited translation
FIGURE 6. Effect of McC on tRNA aminoacyla-
tion in wheat germ extract. A, aminoacylation
reactions in wheat germ extract were carried out
with radioactive leucine and aspartate in the pres-
ence or absence of intact or processed McC as
indicated. B, effect of McC preincubation with
wheat germ extract (WGE) on tRNA aminoacyla-
tion in E. coli extract. WGE alone (bars at the left),
intact McC (bars at the middle), or WGE and intact
McC (bars at the right) were added to the E. coli
aminoacylation reaction and incorporation of
radioactive leucine or aspartate into trichloroace-
tic acid-insoluble fraction was followed.
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in this system (data not shown). Surprisingly, intact McC, which was
used as a control, also inhibited translation in wheat germ extract
(data not shown). Wheat AspRS appeared to be the target of inhibi-
tion because aminoacylation of tRNAAsp but not tRNALeu was
affected by both processed and intact McC (Fig. 6A). To explain this
result, we postulate that intact McC is rapidly processed in wheat
germ extract. Indeed, McC preincubated with wheat germ extract
lost its bactericidal activity (data not shown) but inhibited amino-
acylation of tRNAAsp in the E. coli system (Fig. 6B), suggesting that
McC processing activity is either evolutionarily conserved or, alter-
natively, is nonspecific.
DISCUSSION
Our results define the mechanism of translation inhibition by McC
and open ways to designing specific inhibitors of aminoacyl-tRNA syn-
thetases. The following sequence of events is consistent with our data.
McC enters the sensitive cell through an unknown mechanism. During
cell entry or once inside the cytoplasm, McC is processed by an
unknownpeptidase. The processing event produces a non-hydrolyzable
analogue of aspartyl adenylate, with anN-acylphosphoramidate linkage
and an amino propyl group at the phosphate. This compound specifi-
cally inhibits AspRS, which causes inhibition of translation and prevents
further cell growth.
TheN-acylphosphoramidate functionality is found in several natural
products such as phosmidosine (23) and agrocin 84 (24). The synthesis
of aminoacyl adenylate analogs havingN-acylphosphoramidate linkage
has also been reported (25).
The inhibition of AspRS by various analogues of aspartyl adenylate
has been reported recently (26). AspRS inhibition by processed McC
likely occurs at the level of substrate competition. Experiments with
pure AspRS suggest that processedMcC interacts with its target with
high affinity and that the enzyme-inhibitor complex is very stable.
Whereas further structural studies are now required to elucidate the
exact mechanism of McC binding and inhibition, the highly specific
inhibition of Asp-adenylate biosynthesis suggests that it binds the
free enzyme thus effectively hindering subsequent Asp binding and
activation.
The “Trojan horse” two-step mechanism of McC action (uptake of
inactive compound by a sensitive cell, followed by conversion into an
active, inhibitory compound within the cell) has been described for
several unrelated systems whose active moiety is an amino acid cou-
pled to a nucleotide. The antibiotic albomycin is taken inside the cell
by the ferrichrome uptake system and, once inside the cell, is con-
verted to an active form through the action of peptidase N, which
cleaves the ultimate peptide bond of albomycin and releases the
inhibitory aminoacyl-thioribosyl pyrimidine moiety (27). Another
recently described inhibitor, agrocin 84, is imported inside the sen-
sitive cell and, upon processing, generates a non-hydrolyzable ana-
logue of leucyl adenylate, which inhibits LeuRS (24). Agrocin 84-pro-
ducing cells are resistant to the drug due to an additional copy of the
LeuRS gene carried on a plasmid that codes for agrocin 84 biosynthesis
enzymes. The McC producing plasmid does not carry an AspRS gene.
Previously, we showed that at least two genes, mccC and mccE, are
responsible for immunity to McC. The product of mccC is related to
multidrug-efflux transporters and must contribute to McC resistance
by facilitating its efflux outside the producing cell. MccE is a bifunc-
tional protein; one of its domains is related to diaminopimelate decar-
boxylases, whereas the other is very similar to ribosomal protein L7
serine acetyltransferase. It remains to be determined how the enzymatic
activities of this protein contribute to McC resistance.
Because processed McC has no effect on cell growth, the N-terminal
McC hexapeptide (or part thereof) is presumably essential for cell entry.
Uptake systems that are known to participate in the transport of other
microcins and colicins inside the cell (28) do not appear to be involved
in McC transport because mutations affecting the TolC- and TolB-de-
pendent pathways do not lead to McC resistance.5 An ongoing search
for McC-resistant mutants should help to identify genes involved in
McC transport.
Our results open two new avenues of research. From the inhibitory
standpoint, development of processedMcC analogues with amino acids
other than Asp (either through chemical synthesis or genetic engineer-
ing of the mccA gene) may generate specific inhibitors of aminoacyl-
tRNA synthetases other than AspRS. In addition, structure-activity
studies of theMcC peptide itself may permit the sequences required for
cell entry to be defined. This could potentially allow theMcC peptide to
be used as a vehicle to transport other chargedmolecules intoE. coli and
possibly other bacteria.
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